United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pharma & Biotech